Breast Cancer

The accelerated course was safe and effective and did not increase complications in patients with breast cancer post-mastectomy undergoing breast reconstruction.

Study results showed that Black women with breast cancer were more likely to die across all subtypes, with the disparity varying from 17% to 50% depending on subtype.

Compared with chemotherapy, datopotamab deruxtecan (Dato-DXd) did not achieve a statistically significant overall survival (OS) in patients with inoperable or metastatic HR+/HER2-low or negative breast cancer.

Using ultrasound and clinicopathological characteristics, the studied nomograms effectively evaluated recurrence risk in HR-/HER2+ and HR+/HER2+ breast cancer.

Patients with for HER2-positive breast cancer have an increased risk of developing brain tumors.

Pembrolizumab is an anti-programmed death receptor 1 (PD-1) therapy designed to increase the immune system’s ability to detect and fight tumor cells.

The treatment significantly reduced risk of occurrence by 25% compared with endocrine therapy alone.

Data from the second interim analysis of the DETECT V trial, presented at ESMO Congress 2024, suggest that a chemotherapy-free regimen combining dual HER2-targeted therapy with endocrine therapy, particularly with the addition of ribociclib, may be an effective treatment for patients.

Overall survival results from the phase 3 KEYNOTE-522 study provide evidence of improved long-term outcomes from this pembrolizumab-based regimen.

The gut and intratumoral microbiota influence cancer development, progression, and treatment responses, highlighting the potential for treatment strategies that leverage these microbial interactions to enhance cancer therapies.

Disparities continue in younger patients, raising the need for novel interventions to mitigate challenges associated with younger age at diagnosis.

The study authors suggest that annual screening for women aged 40 and older may be beneficial, but warn of the increased risk of false positive results.

The authors stress that health care providers should explain false positive results to their patients, reassure them that results may be negative, and stress the significance of continued screenings.

Expert shares reasons why many women are behind on their annual breast cancer screenings, along with the latest cutting edge treatments in the breast cancer space.

Fam-trastuzumab deruxtecan-nxki has received 4 breakthrough therapy designations, including the latest approval.

The findings provide guidance for clinicians and patients when navigating therapeutic options to establish treatment plans.

Prediction model can accurately predict the risk of nerve damage in patients who received taxane-based chemotherapy.

Tepylute is a ready-to-dilute, injectable formula that reduces preparation time and enable dosing accuracy.

Key opinion leaders (KOLs) provide key takeaways on metastatic breast cancer and early breast cancer, emphasizing the enthusiasm surrounding recent advances in the field and the potential for improved patient outcomes.

Rose DiMarco, PharmD, BCPS, BCOP, shares insights into the evolving treatment landscape for patients with breast cancer with specific mutations.

The panelists share their concluding thoughts on the importance of collaboration between academic and community practices to achieve the best outcomes for their patients, which includes seeking second opinions and incorporating insights from tumor board discussions.

Medical experts discuss their perspectives on therapy approval and the significance of formulary inclusion, emphasizing the need to carefully consider both toxicities and benefits, which may ultimately lead to the operationalization of a drug in clinical practice.

Key opinion leaders (KOLs) discuss the use of CDK4/6 inhibitors in early breast cancer, specifically in patients who have undergone chemotherapy and surgery. They highlight the key factors that help determine which patients are most likely to benefit from receiving these medications.

The panelists discuss the clinical and economic factors that influence treatment decisions for early breast cancer (eBC), as well as the differences between eBC and metastatic breast cancer (mBC) in terms of adverse event management protocols and strategies for optimizing patient adherence.

The addition of ribociclib (Kisqali; Novartis) to endocrine therapy demonstrated a 28% risk reduction in invasive disease-free survival.